Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.89 USD

105.89
175,375

-0.56 (-0.53%)

Updated Nov 11, 2024 10:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

J&J Falls Amid Reports of Criminal Probe Into Talcum Powder

by Zacks Equity Research

The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.

Amgen & Novartis' Alzheimer Studies End in Another Failure

by Zacks Equity Research

Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.

Aimmune Down on Negative ICER Review on Allergy Candidate

by Zacks Equity Research

Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

Amneal (AMRX) Down on Guidance Update & Restructuring Plan

by Zacks Equity Research

Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.

Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill

by Zacks Equity Research

Glaxo's (GSK) phase III study, evaluating the efficacy of switching to Dovato from a three-drug TAF based regimen, meets the primary endpoint.

Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

by Zacks Equity Research

Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.

Novo Nordisk Reports Encouraging Data From Hemophilia Studies

by Zacks Equity Research

Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.

Bayer-J&J Announce Positive Xarelto Data in Children with VTE

by Zacks Equity Research

Bayer's (BAYRY) Xarelto, in the phase III EINSTEIN-Jr study in pediatric patients, shows a similar low risk of VTE or blood clots compared to current standard anticoagulation therapy.

Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline

by Zacks Equity Research

Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.

Aerie Completes Enrollment Under Rhopressa Study in Japan

by Zacks Equity Research

Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab

by Zacks Equity Research

Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.

Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx

by Zacks Equity Research

Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.

Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran

by Zacks Equity Research

Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.

AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label

by Zacks Equity Research

AstraZeneca (AZN) gets positive CHMP opinion for self-administration option for Fasenra and the Fasenra pen and to include outcomes data on Forxiga???s label.

Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer

by Zacks Equity Research

Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by the CHMP for triple-negative breast cancer.

Atara Reports Initial Data for Multiple Sclerosis Candidate

by Zacks Equity Research

Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.

Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View

by Zacks Equity Research

The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.

FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review

by Zacks Equity Research

The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.

Dova Receives Approval for Doptelet in Europe, Stock Up

by Zacks Equity Research

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits

by Zacks Equity Research

Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S. lawyer Beisner to fight its glyphosate litigations.

Sejuti Banerjea headshot

Is Allergan a Good Deal for AbbVie?

by Sejuti Banerjea

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.

Conatus' Emricasan Lags Primary Goal in Liver Function Study

by Zacks Equity Research

Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.

Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

by Zacks Equity Research

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

NVS or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. NVO: Which Stock Is the Better Value Option?

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

by Zacks Equity Research

Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.